Literature DB >> 1290023

Osteocalcin in patients with rheumatoid arthritis--effect of anatomical stages, inflammatory activity and therapy.

H Franck1, T H Ittel, O Tasch, G Herborn, R Rau.   

Abstract

The aim of this study was to investigate whether the degree of inflammatory activity, the anatomical stage and various treatments have an influence on bone turnover in patients with rheumatoid arthritis (RA). Osteocalcin (OC) and other parameters of bone turnover were measured in 131 patients with RA. The mean values of alkaline phosphatase (AP), but not of OC were significantly (P < 0.01) higher in our patients compared to controls. In contrast to AP, OC values increased and correlated significantly (r = +0.33, P < 0.01) with ascending anatomical stage in women not on glucocorticoid treatment. As regards therapy, we found significantly lower OC levels in women receiving steroids compared to controls (P < 0.03) and those being treated with non-steroidal anti-inflammatory drugs (NSAIDs) (P < 0.03), methotrexate (MTX) (P < 0.05), or gold (P < 0.01). Females treated with gold had higher OC levels than patients receiving no antirheumatic drugs (P < 0.03). Furthermore, there was a significantly negative correlation between OC and inflammatory activity [C-reactive protein (CRP)] (r = -0.25, P < 0.003). In conclusion, OC levels were significantly higher (P < 0.032) in patients with advanced (anatomical) stages of RA. In contrast to AP, changes in bone turnover, such as suppression of bone formation by steroids and high inflammatory activity in patients with RA, were easily detected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1290023     DOI: 10.1007/bf00302154

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  34 in total

Review 1.  The special proteins of bone tissue.

Authors:  J T Triffitt
Journal:  Clin Sci (Lond)       Date:  1987-04       Impact factor: 6.124

2.  The effects of monocyte-conditioned medium and interleukin 1 on the synthesis of collagenous and non-collagenous proteins by mouse bone and human bone cells in vitro.

Authors:  J N Beresford; J A Gallagher; M Gowen; M Couch; J Poser; D D Wood; R G Russell
Journal:  Biochim Biophys Acta       Date:  1984-09-07

3.  Generalised and localised bone loss in patients with rheumatoid arthritis.

Authors:  A C Kennedy; D A Smith; H C Anton; W W Buchanan
Journal:  Scand J Rheumatol       Date:  1975       Impact factor: 3.641

4.  Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs.

Authors:  E A Ekenstam; S Ljunghall; R Hällgren
Journal:  Ann Rheum Dis       Date:  1986-06       Impact factor: 19.103

5.  Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids.

Authors:  A Verstraeten; J Dequeker
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

6.  Effect of renal function on plasma levels of bone Gla-protein.

Authors:  P D Delmas; D M Wilson; K G Mann; B L Riggs
Journal:  J Clin Endocrinol Metab       Date:  1983-11       Impact factor: 5.958

7.  Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma.

Authors:  P A Price; S K Nishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

8.  Plasma bone Gla protein concentrations in healthy adults. Dependence on sex, age, and glomerular filtration.

Authors:  J S Johansen; K Thomsen; C Christiansen
Journal:  Scand J Clin Lab Invest       Date:  1987-06       Impact factor: 1.713

9.  Alkaline phosphatase isoenzymes and osteocalcin in serum of normal subjects.

Authors:  K K Steinberg; T N Rogers
Journal:  Ann Clin Lab Sci       Date:  1987 Jul-Aug       Impact factor: 1.256

10.  [ Serum osteocalcin in chronic polyarthritis in stage III].

Authors:  E Hermann; A Aeschlimann; W Müller
Journal:  Z Rheumatol       Date:  1987 May-Jun       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.